A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).
BACKGROUND
We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC).


METHODS
Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual acuity, fluorescein angiography and optical coherent tomography before, 1, 3 and 6 months after treatment.


RESULTS
All patients showed improvement in visual acuity, fluorescein angiographic leakage, and reduced or resolved neurosensory detachment following treatment.


CONCLUSIONS
Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.
Torres-Soriano
Mitzy E
ME
Retina Service, Asociacion Para Evitar la Ceguera, Hospital Dr. Luis Sánchez Bulnes, Vicente García Torres 46, San Lucas Coyoacan, 04030 Coyoacan, México City, México. mitzytorres@yahoo.com
García-Aguirre
Gerardo
G
Kon-Jara
Verónica
V
Ustariz-Gonzáles
Orlando
O
Abraham-Marín
Maura
M
Ober
Michael D
MD
Quiroz-Mercado
Hugo
H
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002825:Chorioretinitis / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010857:Pigment Epithelium of Eye / Q000473:pathology; D010865:Pilot Projects; D044967:Serum; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab